| EASL clinical practice guidelines: management of hepatocellular carcinoma PR Galle, A Forner, JM Llovet, V Mazzaferro, F Piscaglia, JL Raoul, ... Journal of hepatology 69 (1), 182-236, 2018 | 12094* | 2018 |
| A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement M Eslam, PN Newsome, SK Sarin, QM Anstee, G Targher, ... Journal of hepatology 73 (1), 202-209, 2020 | 3842 | 2020 |
| EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease European Association for the Study of the Liver (EASL), European Association ... Obesity facts 9 (2), 65-90, 2016 | 2744 | 2016 |
| Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis AJ Van Der Meer, BJ Veldt, JJ Feld, H Wedemeyer, JF Dufour, F Lammert, ... Jama 308 (24), 2584-2593, 2012 | 1919 | 2012 |
| Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study A Rauch, Z Kutalik, P Descombes, T Cai, J Di Iulio, T Mueller, M Bochud, ... Gastroenterology 138 (4), 1338-1345. e7, 2010 | 1487 | 2010 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1211 | 2019 |
| NASH limits anti-tumour surveillance in immunotherapy-treated HCC D Pfister, NG Núñez, R Pinyol, O Govaere, M Pinter, M Szydlowska, ... Nature 592 (7854), 450-456, 2021 | 975 | 2021 |
| Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis S McPherson, T Hardy, JF Dufour, S Petta, M Romero-Gomez, M Allison, ... Official journal of the American College of Gastroenterology| ACG 112 (5 …, 2017 | 802 | 2017 |
| Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions L Bolondi, A Burroughs, JF Dufour, PR Galle, V Mazzaferro, F Piscaglia, ... Seminars in liver disease 32 (04), 348-359, 2012 | 774 | 2012 |
| TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease YL Liu, HL Reeves, AD Burt, D Tiniakos, S McPherson, JBS Leathart, ... Nature communications 5 (1), 4309, 2014 | 743 | 2014 |
| Carriage of the PNPLA3 rs738409 C> G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma YL Liu, GL Patman, JBS Leathart, AC Piguet, AD Burt, JF Dufour, CP Day, ... Journal of hepatology 61 (1), 75-81, 2014 | 607 | 2014 |
| Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 … M Manns, D Samuel, EJ Gane, D Mutimer, G McCaughan, M Buti, ... The Lancet Infectious Diseases 16 (6), 685-697, 2016 | 524 | 2016 |
| Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis JF Dufour, CM Oneta, JJ Gonvers, F Bihl, A Cerny, JM Cereda, JF Zala, ... Clinical Gastroenterology and Hepatology 4 (12), 1537-1543, 2006 | 508 | 2006 |
| Angiogenesis and hepatocellular carcinoma D Semela, JF Dufour Journal of hepatology 41 (5), 864-880, 2004 | 478 | 2004 |
| Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆ QM Anstee, R Darlay, S Cockell, M Meroni, O Govaere, D Tiniakos, ... Journal of hepatology 73 (3), 505-515, 2020 | 437 | 2020 |
| Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials SA Harrison, VWS Wong, T Okanoue, N Bzowej, R Vuppalanchi, ... Journal of hepatology 73 (1), 26-39, 2020 | 406 | 2020 |
| Reversibility of hepatic fibrosis in autoimmune hepatitis JF Dufour, R DeLellis, MM Kaplan Annals of internal medicine 127 (11), 981-985, 1997 | 396 | 1997 |
| Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH M Dudek, D Pfister, S Donakonda, P Filpe, A Schneider, M Laschinger, ... Nature 592 (7854), 444-449, 2021 | 371 | 2021 |
| Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C PY Bochud, T Cai, K Overbeck, M Bochud, JF Dufour, B Müllhaupt, ... Journal of hepatology 51 (4), 655-666, 2009 | 363 | 2009 |
| Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests M Masoodi, A Gastaldelli, T Hyötyläinen, E Arretxe, C Alonso, M Gaggini, ... Nature reviews Gastroenterology & hepatology 18 (12), 835-856, 2021 | 320 | 2021 |